Cargando…
Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial
BACKGROUND: We report the clinical efficacy against COVID-19 infection of BBV152, a whole virion inactivated SARS-CoV-2 vaccine formulated with a toll-like receptor 7/8 agonist molecule adsorbed to alum (Algel-IMDG) in Indian adults. METHODS: We did a randomised, double-blind, placebo-controlled, mu...
Autores principales: | Ella, Raches, Reddy, Siddarth, Blackwelder, William, Potdar, Varsha, Yadav, Pragya, Sarangi, Vamshi, Aileni, Vinay K, Kanungo, Suman, Rai, Sanjay, Reddy, Prabhakar, Verma, Savita, Singh, Chandramani, Redkar, Sagar, Mohapatra, Satyajit, Pandey, Anil, Ranganadin, Pajanivel, Gumashta, Raghavendra, Multani, Manish, Mohammad, Shameem, Bhatt, Parul, Kumari, Laxmi, Sapkal, Gajanan, Gupta, Nivedita, Abraham, Priya, Panda, Samiran, Prasad, Sai, Bhargava, Balram, Ella, Krishna, Vadrevu, Krishna Mohan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584828/ https://www.ncbi.nlm.nih.gov/pubmed/34774196 http://dx.doi.org/10.1016/S0140-6736(21)02000-6 |
Ejemplares similares
-
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021) -
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial
por: Ella, Raches, et al.
Publicado: (2021) -
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152)
por: Sunagar, Raju, et al.
Publicado: (2022) -
Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2–18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study
por: Vadrevu, Krishna Mohan, et al.
Publicado: (2022) -
A multi-centre, post-marketing surveillance study of Vi polysaccharide–tetanus toxoid conjugate vaccine (Typbar TCV®) in India
por: Reddy, Raghu, et al.
Publicado: (2021)